about
Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095.Postoperative cerebellar mutism in adult patients with Lhermitte-Duclos disease.The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancerComparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.Intra-individual comparison of ¹⁸F-FET and ¹⁸F-DOPA in PET imaging of recurrent brain tumors.Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI.Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.[Chronic abdominal aortic graft infection : Detection with 18F-FDG-PET/CT].Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate CancerReply to Reske et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue.PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer.Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617.Detection of cranial meningiomas: comparison of ⁶⁸Ga-DOTATOC PET/CT and contrast-enhanced MRI.Erratum to: Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT.18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics.Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study.Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI.The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer.Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer.[¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy.Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: a next step for imaging of recurrent prostate cancer-preliminary results.PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.PSMA Theranostics: Current Status and Future Directions.Impact of 18F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy.Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future ApplicationsImpact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
P50
Q33581903-CC426E8C-F547-411F-90AB-9A1D92ABAB19Q33644635-02196B29-9D07-4E39-AB6E-9F2F5382CAD7Q35043569-EE90430F-B856-4B7C-926C-9B8B88187380Q35604902-9094ADCE-0B72-4F0B-A4DF-CFA7125A06A3Q36109230-649FCE26-481B-42AE-A43E-055CF1522D9AQ37350456-8A0AB7D6-B5ED-4F57-A222-D5D9A3B2FC9FQ37554235-9DCC4DFA-8715-40F4-B3C2-67A7A0C89EC0Q37580486-F11FDF6E-F3A1-4E04-B8A1-49F416DE2BEAQ38683427-8DB7AB5E-48AF-40B4-8250-81A296812282Q38935086-58E8CBD5-3419-43CA-B091-77C3C43A60B2Q38970132-EAC55273-39BD-4282-AED9-A57D137AE9F4Q39710843-C147566A-CB25-4054-BFDB-D4C9668D45F2Q40365278-96903C7A-9A26-4755-A827-E7EC7D880E19Q40529844-A6BFCAC1-1DB1-480C-84F9-F0D04CE14B34Q40621372-40745378-06F5-419B-AB26-47619630CF78Q41905456-4990B764-702A-4261-935B-A2EA61C44B21Q44280610-912ED959-2841-4AC0-A0E3-7D2F94F2CBF9Q44659722-10AC8415-EFCD-4969-83EA-10B197F8AF28Q45328377-73CF5BB5-874E-4F6E-8FA8-BE1F48E42537Q47107463-95E9C2C5-5905-41D0-8C1F-FACDF35D068EQ47661611-E3314321-E7FE-447B-A015-6A1926DED7C1Q48214229-86261071-BBF0-4363-9834-FA8E4829695AQ48905216-75E09D5A-5FC1-4364-8F6D-0E426D7AF6D4Q50248450-44A804B0-4040-4CC3-80FB-3D848A20BDF6Q51160960-BE8495FE-4E0B-4E5A-8965-D0321AF82623Q52654885-B1024EA7-07DC-4211-A668-BC145BEBCE16Q52873027-12F499A7-CE58-4B5D-834F-6BB92F67A9FEQ52940451-6AE4244D-8A0D-415E-9BD1-69177F669ECAQ52956017-1D342AFD-5283-45F4-88AE-545F31BD29FAQ52989703-B6CEC140-3BB3-46A8-8A81-97542F804395Q53031483-201FCB5E-F310-445B-B864-7A1A991FE1A3Q53045254-0A462748-2DEF-4470-9901-5F38F8CD54A6Q53084377-09242279-14D0-45CD-A12A-E5B5A28B0F20Q53098130-CE679BF7-3D59-4DCD-9281-2C1520018FFFQ53131398-EBCA6855-7B7B-48DE-8FA5-1FC8532136FAQ53176385-6383E1C6-0AB3-4B26-ABF3-7B09F070D8F9Q55023828-412714ED-8D4C-41C6-8445-83DB69CE47BFQ55031317-2107B49A-6D52-4140-B85A-F84A3BD2696DQ57171336-908A9623-BE7F-4EB0-944B-5B99D82FCB7AQ63966560-D269FB4C-F692-4E86-9625-6FA812D381E1
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-4492-4243
@en
name
Ali Afshar-Oromieh
@ast
Ali Afshar-Oromieh
@en
Ali Afshar-Oromieh
@es
Ali Afshar-Oromieh
@nl
type
label
Ali Afshar-Oromieh
@ast
Ali Afshar-Oromieh
@en
Ali Afshar-Oromieh
@es
Ali Afshar-Oromieh
@nl
prefLabel
Ali Afshar-Oromieh
@ast
Ali Afshar-Oromieh
@en
Ali Afshar-Oromieh
@es
Ali Afshar-Oromieh
@nl
P214
P106
P214
P31
P496
0000-0002-4492-4243
P7859
viaf-15872504